Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 227

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 227
---
 internationally, cannot be predicted with certainty and
such reform, legislation, regulation, or initiatives may adversely affect the performance of a potential Business Combination.

Technical
expertise is also crucial in the life science industry as the products produced in these sectors are complex - it would take the average
investor significant time to understand the factors that affect the product’s chances of success. Even large, well-established
financial institutions typically have a poor track record when it comes to forecasting the performance of companies in the biopharmaceuticals
or healthcare space. Therefore, technical expertise is crucial in these industries, especially at the management level of companies.
There is risk with certain companies in this sector that may not have the right level of technical expertise at the management level
or management is valuation-driven with stronger focus on profitability than having the technical expertise of understanding how research
findings (e.g., regarding side effects or comparative benefits of one or more particular treatments, services or products) and technological
innovation (together with patent expirations) may make any particular treatment, service or product less attractive if previously unknown
or underappreciated risks are revealed, or if a more effective, less costly or less risky solution is or becomes available. Any such
development could have an adverse effect on the companies that are target businesses for investment.

Finally,
certain healthcare related companies depend on the exclusive rights or patents for the products they develop and distribute. Patents
have a limited duration and, upon expiration, other companies may market substantially similar “generic” products that are
typically sold at a lower price than the patented product, causing the original developer of the product to lose market share and/or
reduce the price charged for the product, resulting in lower profits for the original developer. As a result, the expiration of patents
may adversely affect the profitability of these companies. The profitability of healthcare related companies may also be affected, among
other factors, by restrictions on government reimbursement for medical expenses, rising or falling costs of medical products and services,
pricing pressure, an increased emphasis on outpatient services, a limited product offering, industry innovation, changes in technologies
and other market developments. Finally, because the products and services of healthcare related companies affect the health and well-being
of many individuals, these companies are especially susceptible to product liability lawsuits.

In
addition, risks inherent in investments in the sustainability sector include, but are not limited to, the following:

    ●
    difficulty
    in competing against established companies who may have greater financial resources and